Synairgen shares have risen sharply this year. The growth of the stock from the beginning of the year to the present time was 5.5%. The lowest point of the fall was in May, falling from 148 pence to a minimum of 98 pence. But in June, the shares soared by 176. Despite this volatility, the company’s shares are still up almost 400% over the past 12 months. Today, Synairgen shares are worth 150 1.56% higher than yesterday’s value. Currently, the company’s future depends on the success of its inhaled drug beta-interferon, which is being tested as a potential treatment for coronavirus. The company’s treatment, SNG001, has shown its effectiveness in initial studies, but there is still a long way to go before full commercialization.
Towards the end of May, the company informed the market that a test of the drug SNG001 showed its effectiveness against SARS-CoV-2 variants. Commenting on the results of the tests, Professor Sir Stephen Holgate, founder of Synairgen, said that studies have confirmed the effect of interferon on viruses, which is a positive point for treatment and only increases its attractiveness for medical professionals.
Paul could do better in his engineering profession where he became a real pro. However, he chose the finance field to find a tranquil environment in his career. Today he creates a good number of great content for our team.